Early adopters.
Medicare claims data reveals the vast majority of oncology practices adopted immunotherapy in the months following FDA approval for each primary site analyzed. | Carroll, JAMA Oncol 2022
With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Medicare claims data reveals the vast majority of oncology practices adopted immunotherapy in the months following FDA approval for each primary site analyzed. | Carroll, JAMA Oncol 2022
Comments
Post a Comment